Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Hepatocellular Carcinoma | Research

Expression and prognostic roles of PRDXs gene family in hepatocellular carcinoma

Authors: Mingxing Xu, Jianliang Xu, Dun Zhu, Rishun Su, Baoding Zhuang, Ruiyun Xu, Lingli Li, Shuxian Chen, Yunbiao Ling

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

As the fourth leading cause of cancer-related death in the world, the therapeutic effect and 5-year overall survival of hepatocellular carcinoma (HCC) are not optimistic. Previous researches indicated that the disorder of PRDXs was related to the occurrence and development of cancers.

Methods

In this study, PRDXs were found in various tumor cell lines by CCLE database analysis. The analysis results of UALCAN, HCCDB and Human Protein Atlas databases showed the expression of PRDXs mRNA and protein in HCC tissues was dysregulated. Besides, UALCAN was used to assess the correlations between PRDXs mRNA as well as methylation levels and clinical characterization.

Results

High expression of PRDX1 or low expression of PRDX2/3 suggested poor prognosis for HCC patients which was demonstrated by Kaplan–Meier Plotter. The genetic alterations and biological interaction network of PRDXs in HCC samples were obtained from c-Bioportal. In addition, LinkedOmics was employed to analyze PRDXs related differentially expressed genes, and on this basis, enrichment of KEGG pathway and miRNAs targets of PRDXs were conducted. The results indicated that these genes were involved in several canonical pathways and certain amino acid metabolism, some of which may effect on the progression of HCC.

Conclusions

In conclusion, the disordered expression of some PRDX family members was associated with the prognosis of HCC patients, suggesting that these PRDX family members may become new molecular targets for the treatment and prognosis prediction of HCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Xue R, Chen L, Zhang C, Fujita M, Li R, Yan SM, et al. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell. 2019;35(6):932.e8-947.e8. CrossRef Xue R, Chen L, Zhang C, Fujita M, Li R, Yan SM, et al. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell. 2019;35(6):932.e8-947.e8. CrossRef
2.
go back to reference Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616.CrossRef Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599–616.CrossRef
3.
go back to reference Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477.e1-491.e1.CrossRef Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477.e1-491.e1.CrossRef
4.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef
5.
go back to reference Riaz A, Lewandowski R, Salem R. Radioembolization in advanced hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1898–901.CrossRef Riaz A, Lewandowski R, Salem R. Radioembolization in advanced hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1898–901.CrossRef
6.
go back to reference Lu M, Zhu WW, Wang X, Tang JJ, Zhang KL, Yu GY, et al. ACOT12-dependent alteration of acetyl-CoA drives hepatocellular carcinoma metastasis by epigenetic induction of epithelial–mesenchymal transition. Cell Metab. 2019;29(4):886.e5-900.e5.CrossRef Lu M, Zhu WW, Wang X, Tang JJ, Zhang KL, Yu GY, et al. ACOT12-dependent alteration of acetyl-CoA drives hepatocellular carcinoma metastasis by epigenetic induction of epithelial–mesenchymal transition. Cell Metab. 2019;29(4):886.e5-900.e5.CrossRef
7.
go back to reference Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567(7747):257–61.CrossRef Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567(7747):257–61.CrossRef
8.
go back to reference Greten TF, Lai CW, Li G, Staveley-O’Carroll KF. Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology. 2019;156(2):510–24.CrossRef Greten TF, Lai CW, Li G, Staveley-O’Carroll KF. Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology. 2019;156(2):510–24.CrossRef
9.
go back to reference Li Z, Zhang H, Han J, Chen Y, Lin H, Yang T. Surface nanopore engineering of 2D MXenes for targeted and synergistic multitherapies of hepatocellular carcinoma. Adv Mater. 2018;30(25):e1706981.CrossRef Li Z, Zhang H, Han J, Chen Y, Lin H, Yang T. Surface nanopore engineering of 2D MXenes for targeted and synergistic multitherapies of hepatocellular carcinoma. Adv Mater. 2018;30(25):e1706981.CrossRef
10.
go back to reference Knoops B, Argyropoulou V, Becker S, Ferte L, Kuznetsova O. Multiple roles of peroxiredoxins in inflammation. Mol Cell. 2016;39(1):60–4.CrossRef Knoops B, Argyropoulou V, Becker S, Ferte L, Kuznetsova O. Multiple roles of peroxiredoxins in inflammation. Mol Cell. 2016;39(1):60–4.CrossRef
11.
go back to reference Yaron-Marcovich D, Dror I, Berkowitz B. Behavior and stability of organic contaminant droplets in aqueous solutions. Chemosphere. 2007;69(10):1593–601.CrossRef Yaron-Marcovich D, Dror I, Berkowitz B. Behavior and stability of organic contaminant droplets in aqueous solutions. Chemosphere. 2007;69(10):1593–601.CrossRef
12.
go back to reference Hopkins BL, Nadler M, Skoko JJ, Bertomeu T, Pelosi A, Shafaei PM, et al. A peroxidase peroxiredoxin 1-specific redox regulation of the novel FOXO3 microRNA target let-7. Antioxid Redox Signal. 2018;28(1):62–77.CrossRef Hopkins BL, Nadler M, Skoko JJ, Bertomeu T, Pelosi A, Shafaei PM, et al. A peroxidase peroxiredoxin 1-specific redox regulation of the novel FOXO3 microRNA target let-7. Antioxid Redox Signal. 2018;28(1):62–77.CrossRef
13.
go back to reference Jeong SJ, Kim S, Park JG, Jung IH, Lee MN, Jeon S, et al. Prdx1 (peroxiredoxin 1) deficiency reduces cholesterol efflux via impaired macrophage lipophagic flux. Autophagy. 2018;14(1):120–33.CrossRef Jeong SJ, Kim S, Park JG, Jung IH, Lee MN, Jeon S, et al. Prdx1 (peroxiredoxin 1) deficiency reduces cholesterol efflux via impaired macrophage lipophagic flux. Autophagy. 2018;14(1):120–33.CrossRef
14.
go back to reference Min Y, Kim MJ, Lee S, Chun E, Lee KY. Inhibition of TRAF6 ubiquitin-ligase activity by PRDX1 leads to inhibition of NFKB activation and autophagy activation. Autophagy. 2018;14(8):1347–58.CrossRef Min Y, Kim MJ, Lee S, Chun E, Lee KY. Inhibition of TRAF6 ubiquitin-ligase activity by PRDX1 leads to inhibition of NFKB activation and autophagy activation. Autophagy. 2018;14(8):1347–58.CrossRef
15.
go back to reference Ying M, Shao X, Jing H, Liu Y, Qi X, Cao J, et al. Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. Blood J Am Soc Hematol. 2018;131(24):2698–711. Ying M, Shao X, Jing H, Liu Y, Qi X, Cao J, et al. Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2. Blood J Am Soc Hematol. 2018;131(24):2698–711.
16.
go back to reference Yan Y, Wladyka C, Fujii J, Sockanathan S. Prdx4 is a compartment-specific H2O2 sensor that regulates neurogenesis by controlling surface expression of GDE2. Nat Commun. 2015;6:7006.CrossRef Yan Y, Wladyka C, Fujii J, Sockanathan S. Prdx4 is a compartment-specific H2O2 sensor that regulates neurogenesis by controlling surface expression of GDE2. Nat Commun. 2015;6:7006.CrossRef
17.
go back to reference Zhou SL, Zhou ZJ, Hu ZQ, Song CL, Luo YJ, Luo CB, et al. Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence. J Hepatol. 2019;71(6):1152–63. CrossRef Zhou SL, Zhou ZJ, Hu ZQ, Song CL, Luo YJ, Luo CB, et al. Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence. J Hepatol. 2019;71(6):1152–63. CrossRef
18.
go back to reference Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019;68(12):2195–205.CrossRef Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019;68(12):2195–205.CrossRef
19.
go back to reference Wang J, Meng J, Ran W, Lee RJ, Teng L, Zhang P, et al. Hepatocellular carcinoma growth retardation and PD-1 blockade therapy potentiation with synthetic high-density lipoprotein. Nano Lett. 2019;19(8):5266–76.CrossRef Wang J, Meng J, Ran W, Lee RJ, Teng L, Zhang P, et al. Hepatocellular carcinoma growth retardation and PD-1 blockade therapy potentiation with synthetic high-density lipoprotein. Nano Lett. 2019;19(8):5266–76.CrossRef
20.
go back to reference Hampton MB, Vick KA, Skoko JJ, Neumann CA. Peroxiredoxin involvement in the initiation and progression of human cancer. Antioxid Redox Signal. 2018;28(7):591–608.CrossRef Hampton MB, Vick KA, Skoko JJ, Neumann CA. Peroxiredoxin involvement in the initiation and progression of human cancer. Antioxid Redox Signal. 2018;28(7):591–608.CrossRef
21.
go back to reference Aguilar-Melero P, Prieto-Alamo MJ, Jurado J, Holmgren A, Pueyo C. Proteomics in HepG2 hepatocarcinoma cells with stably silenced expression of PRDX1. J Proteom. 2013;79:161–71.CrossRef Aguilar-Melero P, Prieto-Alamo MJ, Jurado J, Holmgren A, Pueyo C. Proteomics in HepG2 hepatocarcinoma cells with stably silenced expression of PRDX1. J Proteom. 2013;79:161–71.CrossRef
22.
go back to reference Zhou S, Han Q, Wang R, Li X, Wang Q, Wang H, et al. PRDX2 protects hepatocellular carcinoma SMMC-7721 cells from oxidative stress. Oncol Lett. 2016;12(3):2217–21.CrossRef Zhou S, Han Q, Wang R, Li X, Wang Q, Wang H, et al. PRDX2 protects hepatocellular carcinoma SMMC-7721 cells from oxidative stress. Oncol Lett. 2016;12(3):2217–21.CrossRef
23.
go back to reference Xu X, Lu D, Zhuang R, Wei X, Xie H, Wang C, et al. The phospholipase A2 activity of peroxiredoxin 6 promotes cancer cell death induced by tumor necrosis factor alpha in hepatocellular carcinoma. Mol Carcinog. 2016;55(9):1299–308.CrossRef Xu X, Lu D, Zhuang R, Wei X, Xie H, Wang C, et al. The phospholipase A2 activity of peroxiredoxin 6 promotes cancer cell death induced by tumor necrosis factor alpha in hepatocellular carcinoma. Mol Carcinog. 2016;55(9):1299–308.CrossRef
24.
go back to reference Fang Y, He J, Janssen HLA, Wu J, Dong L, Shen XZ. Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence. J Dig Dis. 2018;19(3):155–69.CrossRef Fang Y, He J, Janssen HLA, Wu J, Dong L, Shen XZ. Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence. J Dig Dis. 2018;19(3):155–69.CrossRef
25.
go back to reference Zhu GQ, Yang Y, Chen EB, Wang B, Xiao K, Shi SM, et al. Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. J Transl Med. 2019;17(1):203.CrossRef Zhu GQ, Yang Y, Chen EB, Wang B, Xiao K, Shi SM, et al. Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. J Transl Med. 2019;17(1):203.CrossRef
26.
go back to reference Ji D, Li M, Zhan T, Yao Y, Shen J, Tian H, et al. Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients. Carcinogenesis. 2013;34(6):1265–72.CrossRef Ji D, Li M, Zhan T, Yao Y, Shen J, Tian H, et al. Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients. Carcinogenesis. 2013;34(6):1265–72.CrossRef
27.
go back to reference Guo X, Noguchi H, Ishii N, Homma T, Hamada T, Hiraki T, et al. The association of peroxiredoxin 4 with the initiation and progression of hepatocellular carcinoma. Antioxid Redox Signal. 2019;30(10):1271–84.CrossRef Guo X, Noguchi H, Ishii N, Homma T, Hamada T, Hiraki T, et al. The association of peroxiredoxin 4 with the initiation and progression of hepatocellular carcinoma. Antioxid Redox Signal. 2019;30(10):1271–84.CrossRef
28.
go back to reference Annunziata I, van de Vlekkert D, Wolf E, Finkelstein D, Neale G, Machado E, et al. MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat. Nat Commun. 2019;10(1):3623.CrossRef Annunziata I, van de Vlekkert D, Wolf E, Finkelstein D, Neale G, Machado E, et al. MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat. Nat Commun. 2019;10(1):3623.CrossRef
29.
go back to reference Chang L, Zhang D, Shi H, Bian Y, Guo R. MiR-143 inhibits endometrial cancer cell proliferation and metastasis by targeting MAPK1. Oncotarget. 2017;8(48):84384–95.CrossRef Chang L, Zhang D, Shi H, Bian Y, Guo R. MiR-143 inhibits endometrial cancer cell proliferation and metastasis by targeting MAPK1. Oncotarget. 2017;8(48):84384–95.CrossRef
30.
go back to reference Yang YF, Pan YH, Cao Y, Fu J, Yang X, Zhang MF, et al. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of beta-Catenin signaling in hepatocellular carcinoma. Oncotarget. 2017;8(29):47195–205.CrossRef Yang YF, Pan YH, Cao Y, Fu J, Yang X, Zhang MF, et al. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of beta-Catenin signaling in hepatocellular carcinoma. Oncotarget. 2017;8(29):47195–205.CrossRef
31.
go back to reference Zheng MJ, Wang J, Wang HM, Gao LL, Li X, Zhang WC, et al. Decreased expression of peroxiredoxin1 inhibits proliferation, invasion, and metastasis of ovarian cancer cell. OncoTarget Ther. 2018;11:7745–61.CrossRef Zheng MJ, Wang J, Wang HM, Gao LL, Li X, Zhang WC, et al. Decreased expression of peroxiredoxin1 inhibits proliferation, invasion, and metastasis of ovarian cancer cell. OncoTarget Ther. 2018;11:7745–61.CrossRef
32.
go back to reference Wang R, Wei J, Zhang S, Wu X, Guo J, Liu M, et al. Peroxiredoxin 2 is essential for maintaining cancer stem cell-like phenotype through activation of Hedgehog signaling pathway in colon cancer. Oncotarget. 2016;7(52):86816–28.CrossRef Wang R, Wei J, Zhang S, Wu X, Guo J, Liu M, et al. Peroxiredoxin 2 is essential for maintaining cancer stem cell-like phenotype through activation of Hedgehog signaling pathway in colon cancer. Oncotarget. 2016;7(52):86816–28.CrossRef
33.
go back to reference Lv Z, Wei J, You W, Wang R, Shang J, Xiong Y, et al. Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer. J Transl Med. 2017;15(1):257.CrossRef Lv Z, Wei J, You W, Wang R, Shang J, Xiong Y, et al. Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer. J Transl Med. 2017;15(1):257.CrossRef
34.
go back to reference Li KK, Pang JC, Lau KM, Zhou L, Mao Y, Wang Y, et al. MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol. 2013;23(4):413–25.CrossRef Li KK, Pang JC, Lau KM, Zhou L, Mao Y, Wang Y, et al. MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol. 2013;23(4):413–25.CrossRef
Metadata
Title
Expression and prognostic roles of PRDXs gene family in hepatocellular carcinoma
Authors
Mingxing Xu
Jianliang Xu
Dun Zhu
Rishun Su
Baoding Zhuang
Ruiyun Xu
Lingli Li
Shuxian Chen
Yunbiao Ling
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02792-8

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine